KSE - Delayed Quote KRW

Daewoong Pharmaceutical Co., Ltd (069620.KS)

157,900.00
-400.00
(-0.25%)
At close: 3:30:24 PM GMT+9
Loading Chart for 069620.KS
  • Previous Close 158,300.00
  • Open 159,700.00
  • Bid 157,500.00 x --
  • Ask 157,600.00 x --
  • Day's Range 155,200.00 - 161,700.00
  • 52 Week Range 100,100.00 - 171,600.00
  • Volume 22,076
  • Avg. Volume 36,978
  • Market Cap (intraday) 1.817T
  • Beta (5Y Monthly) 0.59
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date Aug 7, 2025 - Aug 11, 2025
  • Forward Dividend & Yield 600.00 (0.38%)
  • Ex-Dividend Date Dec 27, 2024
  • 1y Target Est 201,875.00

Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. Daewoong Pharmaceutical Co., Ltd. has a collaboration agreement with Salipro Biotech AB for the use of Salipro platform for stabilizing challenging membrane proteins to advance drug discovery. The company was founded in 1945 and is headquartered in Seoul, South Korea.develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. Daewoong Pharmaceutical Co., Ltd. has a collaboration agreement with Salipro Biotech AB for the use of Salipro platform for stabilizing challenging membrane proteins to advance drug discovery. The company was founded in 1945 and is headquartered in Seoul, South Korea.

www.daewoong.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 069620.KS

View more

Performance Overview: 069620.KS

Trailing total returns as of 6/16/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

069620.KS
24.92%
KOSPI Composite Index (^KS11)
22.80%

1-Year Return

069620.KS
53.01%
KOSPI Composite Index (^KS11)
6.82%

3-Year Return

069620.KS
5.48%
KOSPI Composite Index (^KS11)
20.20%

5-Year Return

069620.KS
12.67%
KOSPI Composite Index (^KS11)
37.82%

Compare to: 069620.KS

Select to analyse similar companies using key performance metrics; select up to four stocks.

Statistics: 069620.KS

View more

Valuation Measures

Annual
As of 6/13/2025
  • Market Cap

    1.82T

  • Enterprise Value

    2.38T

  • Trailing P/E

    47.32

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.26

  • Price/Book (mrq)

    2.26

  • Enterprise Value/Revenue

    1.65

  • Enterprise Value/EBITDA

    19.07

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.67%

  • Return on Assets (ttm)

    5.08%

  • Return on Equity (ttm)

    3.78%

  • Revenue (ttm)

    1.44T

  • Net Income Avi to Common (ttm)

    38.48B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    102.86B

  • Total Debt/Equity (mrq)

    75.43%

  • Levered Free Cash Flow (ttm)

    -157.19B

Research Analysis: 069620.KS

View more

Company Insights: 069620.KS

Research reports: 069620.KS

View more

People Also Watch